PDCD1 and neoplasm: One of the most promising strategies for enhancing anti-tumor immune responses is the blockade of inhibitory immune checkpoints, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or PD-1 ligand (PD-L1) [1].